Crossmark

Direct conversion of ustekinumab therapy is more beneficial than infliximab-optimized therapy in patients with Crohn’s disease who develop secondary loss of response to infliximab

Crossref DOI link: https://doi.org/10.1186/s12876-025-04319-7

Published Online: 2025-09-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Lin

Xu, Xuemei

Wang, Jing

Xie, Li

Niu, Xiaoping
Funding

Funding for this research was provided by:

Key Research Project of Wannan Medical College (No.WK2022ZF03)

Introduction of Talents Special Research Fund Project (No.YR202427)

Key project of Anhui University Scientific Research Program (No.2024AH051969)

Anhui Province clinical medical research transformation project (No.202427b10020077)
License Information

Text and Data Mining valid from 2025-09-29

Version of Record valid from 2025-09-29
More Information

Article History

Received: 29 April 2025

Accepted: 9 September 2025

First Online: 29 September 2025

Declarations

:

: The study protocol was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of the First Affiliated Hospital of Wannan Medical College (No. 2024SR219). All participants provided informed consent. A clinical trial registration number was not applicable.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below